Overview
Cerevel Therapeutics was a clinical-stage neuroscience company developing selective receptor-targeted therapies for schizophrenia, Parkinson's disease, and epilepsy, best known for emraclidine, a muscarinic receptor agonist for schizophrenia. Cerevel was acquired by AbbVie in 2024 for approximately $8.7 billion.
More in Neuropharmaceuticals
Latest industry news
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Company details
Category
💊 Neuropharmaceuticals
Location
Cambridge, USA
Funding
Acquired · AbbVie 2024
Website
www.cerevel.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →